ReviewNature reviews. Drug discovery2017
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.
Review in Nature reviews. Drug discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 410 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
410 citing papers in PubMed, 2 syntheses or guidelines pooled it, 767 citations in OpenAlex.
- A bibliometric analysis on discovering anti-quorum sensing agents against clinically relevant pathogens: current status, development, and future directions.Frontiers in microbiology · 2023Pooled it
- The Role of Virulence Factors in Neonatal Sepsis Caused by Enterobacterales: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Indole decreases the virulence of enterotoxigenic Escherichia coli.World journal of microbiology & biotechnology · 2026Article
- In Vitro antibacterial, anti-biofilm, and virulence-modulating activity of Cinnamomum verum-mediated iron oxide nanoparticles against carbapenem-resistant uropathogenic Escherichia coli.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- The small molecule regacin binds a conserved pocket in RegA to inhibit the expression of bacterial virulence factors.bioRxiv : the preprint server for biology · 2026Article
- Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli.ACS infectious diseases · 2026Article
- Repression of Virulence in Staphylococcus aureus by 2-Aminothiol-Mediated Quorum Quenching.Angewandte Chemie (International ed. in English) · 2026Article
- Structure-based virulence factor classification using a dual-driven graph transformer with a pretrained language model.Briefings in bioinformatics · 2026Article
- Isoflavones with Multifaceted Activities Synergistically SensitizeAntibiotics (Basel, Switzerland) · 2026Article
- Staphylococcus aureus-vascular endothelium interactions: Mechanisms and therapeutic opportunities.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Review
- Stage V sporulation protein G as a global regulator of biofilm formation and virulence in Staphylococcus species: molecular mechanisms and therapeutic potential.World journal of microbiology & biotechnology · 2026Review
- Gramicidin D as a Multi-Target Antimicrobial Against Staphylococcus aureus: Biofilm Disruption, Virulence Attenuation, Antibiotic Potentiation, and Protein-Peptide Docking Insight.Probiotics and antimicrobial proteins · 2026Article
- PrfA, the master virulence regulator of Listeria monocytogenes: structural-functional insights, regulatory architecture, and antivirulence strategies.Molecular biology reports · 2026Review
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Coumarins Disrupt Cell-Cell Communication and Virulence in Priority Pathogens: Targeting the PQS Signalling System in Pseudomonas aeruginosa.Microbial biotechnology · 2026Article
- Collective fluctuations underlying nanobody inhibitory activity targetingbioRxiv : the preprint server for biology · 2026Article
- Emerging pathogens in urinary tract infections: virulence and phenotypic characterization ofmSphere · 2026Article
- Article
- Imidazo[2,1-Antibiotics (Basel, Switzerland) · 2026Article
350 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The rapid evolution and dissemination of antibiotic resistance among bacterial pathogens are outpacing the development of new antibiotics, but antivirulence agents provide an alternative. These agents can circumvent antibiotic resistance by disarming pathogens of virulence factors that facilitate human disease while leaving bacterial growth pathways - the target of traditional antibiotics - intact. Either as stand-alone medications or together with antibiotics, these drugs are intended to treat bacterial infections in a largely pathogen-specific manner. Notably, development of antivirulence drugs requires an in-depth understanding of the roles that diverse virulence factors have in disease processes. In this Review, we outline the theory behind antivirulence strategies and provide examples of bacterial features that can be targeted by antivirulence approaches. Furthermore, we discuss the recent successes and failures of this paradigm, and new developments that are in the pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.